Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.56 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28857934 | 1.00 | PPARA (0.56) | PPARAPPARGMDM2SLC17A5ACE | |
| SCHEMBL29401307 | 0.91 | SLC17A5 (0.61) | PPARAPPARGSLC17A5ACEMDM4 | |
| SCHEMBL27620508 | 0.91 | SLC17A5 (0.61) | PPARAPPARGSLC17A5ACEMDM4 | |
| SCHEMBL119188 | 0.91 | SLC17A5 (0.61) | PPARAPPARGSLC17A5ACEMDM4 | |
| SCHEMBL29908094 | 0.91 | SLC17A5 (0.61) | PPARAPPARGSLC17A5ACEMDM4 | |
| SCHEMBL7707122 | 0.90 | PPARA (0.55) | PPARAPPARGMDM2SLC17A5ACE | |
| SCHEMBL16634948 | 0.90 | SLC17A5 (0.57) | PPARAPPARGMDM2SLC17A5ACE | |
| SCHEMBL29594267 | 0.90 | SLC17A5 (0.57) | PPARAPPARGMDM2SLC17A5ACE | |
| SCHEMBL2310132 | 0.87 | MDM2 (0.60) | MDM2MDM4TP53CASP3 | |
| SCHEMBL29402409 | 0.87 | MDM2 (0.60) | MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-04-30 | — | — | US | claimed |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2026-01-20 | — | — | US | claimed |
| CN-118255842-A | Solid-liquid phase synthesis method of linaclotide | 苏州特瑞药业股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| US-20220249644-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2022-08-11 | — | — | US | claimed |
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-04-30 | — | — | US | disclosed |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2026-01-20 | — | — | US | disclosed |
| CN-119708114-A | Positioning cyclization method of three pairs of disulfide bonds in polypeptide synthesis process | 厦门胜泽泰医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118255842-A | Solid-liquid phase synthesis method of linaclotide | 苏州特瑞药业股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116813740-A | Solid phase synthesis method of cono anti-wrinkle agent | 瑞博(苏州)制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20130338085-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. | 2013-12-19 | — | — | US | disclosed |
| US-8492518-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS LTD. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8293870-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2399599-A2 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100197607-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2010-08-05 | — | — | US | disclosed |
| US-20090275520-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2009-11-05 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | SCN8A, SCN9A, VIP | PPARA 4831/4885PPARG 4851/4885MDM2 4474/4885 |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VIP, MLEC, SEC16A | PPARA 3975/4885PPARG 3854/4885MDM2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.